Syremis Therapeutics Appoints Dr. Aaron Koenig as Chief Medical Officer
Syremis Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health disorders, today announced the appointment of Aaron Koenig, MD, as Chief Medical Officer.
Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions
Syremis Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health, today announced its launch with a $165 million financing. The Series A, co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet will support the advancement of Syremis’ pipeline through clinical proof of concept.
